Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
Impel Pharmaceuticals (NASDAQ: IMPL) announced that Adrian Adams, CEO, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 1:00 p.m. ET in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel Pharmaceuticals (NASDAQ: IMPL) announced that Adrian Adams, CEO, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 1:00 p.m. ET in New York, NY. A live webcast of the event will be available on the company’s website, with a replay accessible for 90 days.
Impel Pharmaceuticals develops transformative therapies for diseases with high unmet needs, including the approved Trudhesa nasal spray for migraine treatment and the developing INP105 for agitation in autism.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was -4.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on Tuesday, November 15, 2022 at 1:00 p.m. ET in New York, NY.
A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers, and is developing, treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.